Standard Operating Procedures for Chinese Medicine Data Monitoring Committees of Clinical Studies

Jun LIU; Nian WANG; Hai-xia DANG; Bing-wei CHEN; Li ZHANG; Chong ZOU; Cheng-liang ZHONG; Ju-kai HUANG; Qiong LIU; Ya-nan YU; Meng JIANG; Wei-xiong LIANG; Qi-guang CHEN; Yong-yan WANG; Chun-ti SHEN; Zhong WANG; Zhong WANG

doi:10.1007/s11655-020-3439-2

Your Location：

Home >

Browse articles >

Standard Operating Procedures for Chinese Medicine Data Monitoring Committees of Clinical Studies

Regulation and Guideline | Updated：2021-09-01

- Standard Operating Procedures for Chinese Medicine Data Monitoring Committees of Clinical Studies
- Chinese Journal of Integrative Medicine Vol. 27, Issue 7, Pages: 483-489(2021)
- Affiliations：
  
  1.Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing (100700), China
  2.China Academy of Chinese Medical Sciences, Beijing(100700), China
  3.School of Public Health, Southeast University, Nanjing (210009), China
  4.Dongfang Hospital Affiliated to Beijing University of Chinese Medicine, Beijing (100078), China
  5.Jiangsu Provincial Hospital of Traditional Chinese Medicine(Affiliated Hospital of Nanjing University of Traditional Chinese Medicine), Nanjing (210029), China
  6.First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin(300381), China
  7.Guangdong Hospital of Traditional Chinese Medicine, Guangzhou (510120), China
  8.Changzhou Traditional Chinese Medicine Hospital, Changzhou, Jiangsu Province(213004), China
- Author bio：
  
  Prof. WANG Zhong, E-mail: zhonw@vip.sina.com
  Prof. WANG Zhong, E-mail: zhonw@vip.sina.com
- Funds：
- DOI：10.1007/s11655-020-3439-2
  CLC：
- Published：01 July 2021，
  
  Published Online：10 November 2020，
  
  Accepted：16 September 2020
Scan for full text
Jun LIU, Nian WANG, Hai-xia DANG, et al. Standard Operating Procedures for Chinese Medicine Data Monitoring Committees of Clinical Studies. [J]. Chinese Journal of Integrative Medicine 27(7):483-489(2021)
DOI：

Jun LIU, Nian WANG, Hai-xia DANG, et al. Standard Operating Procedures for Chinese Medicine Data Monitoring Committees of Clinical Studies. [J]. Chinese Journal of Integrative Medicine 27(7):483-489(2021) DOI： 10.1007/s11655-020-3439-2.

摘要

Abstract

Although there is guidance from different regulatory agencies

there are opportunities to bring greater consistency and stronger applicability to address the practical issues of establishing and operating a data monitoring committee (DMC) for clinical studies of Chinese medicine. We names it as a Chinese Medicine Data Monitoring Committee (CMDMC). A panel composed of clinical and statistical experts shared their experience and thoughts on the important aspects of CMDMCs. Subsequently

a community standard on CMDMCs (T/CACM 1323-2019) was issued by the China Association of Chinese Medicine on September 12

2019. This paper summarizes the key content of this standard to help the sponsors of clinical studies establish and operate CMDMCs

which will further develop the scientific integrity and quality of clinical studies.

关键词

Keywords

data monitoring committeeChinese Medicine Data Monitoring Committeeclinical trialcommunity standardChinese medicine

references

TR Fleming, DL DeMets, MT Roe, J Wittes, KA Calis, AN Vora, et al. Data monitoring committees: promoting best practices to address emerging challenges. Clin Trials 2017;14:115-123.

Committee for Medicinal Products for Human Use; Efficacy Working Party; Committee for Release for Consultation.Committee for Medicinal Products for Human Use (CHMP) guideline on data monitoring committees. Stat Med 2006;25:1639-1645.

European Medicines Agency. Guideline on data monitoring committees 2005. Available at: http://www.emea.europa.eu/pdfs/human/ewp/587203en.pdfhttp://www.emea.europa.eu/pdfs/human/ewp/587203en.pdf.

Food and Drug Administration. Guidance for clinical trial sponsors establishment and operation of clinical trial data monitoring committees 2006. Available at: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm127073.pdfhttp://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm127073.pdf.

L Wang, J Liu, HX Dang, Z Wang, CT Shen. Data and safety monitoring of Danhong injection in Ⅳ clinical trials. J Chin Pharmaceut Sci (Chin) 2015;50:375-378.

SC Chow, M Chang. Adaptive design methods in Clinical trials. Chapman & Hall/CRC, Boca Raton, 2007.

DL DeMets, SS Ellenberg. Data monitoring committees-expect the unexpected. N Engl J Med 2016; 375:1365-1371.

NA Listed. ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group. Stat Med 1999;18:1905-1942.

JM Lachin. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.Stat Med 2006;25:3348-3365.

SM Snapinn. Monitoring clinical trials with a conditional probability stopping rule. Stat Med 1992;11:659-672.

Y Yu, S Hu, G Li, J Xue, Z Li, X Liu, X Yang, et al.Comparative effectiveness of Di'ao Xin Xue Kang capsule and Compound Danshen tablet in patients with symptomatic chronic stable angina. Sci Rep 2014;4:7058.

B Li, Y Wang, J Lu, J Liu, Y Yuan, Y Yu, et al. Evaluating the effects of Danhong injection in treatment of acute ischemic stroke: study protocol for a multicenter randomized controlled trial. Trials 2015;16:561.

PQ Wang, DD Li, W Dong, J Liu, YN Yu, CT Shen, et al.Danhong Injection in the treatment of chronic stable angina:study protocol for a randomized controlled trial. Trials 2015;16:474.

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Chemical Composition, Pharmacological Effects and Clinical Applications of Cinobufacini

Immunomodulatory Function of Pien Tze Huang in T Cell-Mediated Anti-tumor Activity against B16-F10, MC38 and Hep1-6 Tumor Models

Safflower Yellow Inhibits Progression of Hepatocellular Carcinoma by Modulating Immunological Tolerance via FAK Pathway

Immunoregulatory and Anti-cancer Activities of Combination Treatment of Novel Four-Herb Formula and Doxorubicin in 4T1-Breast Cancer Bearing Mice

Related Author

No data

Related Institution

Graduate School, Beijing University of Chinese Medicine

Department of Oncology, Xiyuan Hospital, China Academy of Chinese Medical Sciences

Department of Oncology, Central Hospital of Ankang City

Key Laboratory of Shaanxi Administration of Traditional Chinese Medicine for TCM Compatibility, Shaanxi University of Chinese Medicine

State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Faculty of Medicine and Life Science, Xiamen University

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰